These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 30511936)

  • 1. Interval cancers after negative immunochemical test compared to screen and non-responders' detected cancers in Slovenian colorectal cancer screening programme.
    Mlakar DN; Bric TK; Škrjanec AL; Krajc M
    Radiol Oncol; 2018 Jul; 52(4):413-421. PubMed ID: 30511936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of interval cancers in faecal immunochemical test colorectal screening programmes in Italy.
    Giorgi Rossi P; Carretta E; Mangone L; Baracco S; Serraino D; Zorzi M;
    J Med Screen; 2018 Mar; 25(1):32-39. PubMed ID: 28195508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing.
    van der Vlugt M; Grobbee EJ; Bossuyt PMM; Bos A; Bongers E; Spijker W; Kuipers EJ; Lansdorp-Vogelaar I; Spaander MCW; Dekker E
    Gastroenterology; 2017 Aug; 153(2):439-447.e2. PubMed ID: 28483499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interval colorectal cancers after negative faecal immunochemical test in a 13-year screening programme.
    Zorzi M; Hassan C; Senore C; Capodaglio G; Turrin A; Narne E; Mussato A; Rizzato S; Chinellato E; Zamberlan S; Repici A; Rugge M
    J Med Screen; 2021 Jun; 28(2):131-139. PubMed ID: 32393153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interval cancers in a guaiac-based colorectal cancer screening programme: Consequences on sensitivity.
    Blom J; Törnberg S
    J Med Screen; 2017 Sep; 24(3):146-152. PubMed ID: 28142309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Occurrence and characteristics of faecal immunochemical screen-detected cancers vs non-screen-detected cancers: Results from a Flemish colorectal cancer screening programme.
    van de Veerdonk W; Hoeck S; Peeters M; Van Hal G; Francart J; De Brabander I
    United European Gastroenterol J; 2020 Mar; 8(2):185-194. PubMed ID: 32213071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of screening programme using the faecal immunochemical test on stage of colorectal cancer: Results from the IMPATTO study.
    Vicentini M; Zorzi M; Bovo E; Mancuso P; Zappa M; Manneschi G; Mangone L; Giorgi Rossi P;
    Int J Cancer; 2019 Jul; 145(1):110-121. PubMed ID: 30585621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved 5-year survival of patients with immunochemical faecal blood test-screen-detected colorectal cancer versus non-screening cancers in northern Italy.
    Parente F; Vailati C; Boemo C; Bonoldi E; Ardizzoia A; Ilardo A; Tortorella F; Cereda D; Cremaschini M; Moretti R
    Dig Liver Dis; 2015 Jan; 47(1):68-72. PubMed ID: 25306524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interval cancers using a quantitative faecal immunochemical test (FIT) for haemoglobin when colonoscopy capacity is limited.
    Digby J; Fraser CG; Carey FA; Lang J; Stanners G; Steele RJ
    J Med Screen; 2016 Sep; 23(3):130-4. PubMed ID: 26589788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of immunochemical faecal occult blood testing on colorectal cancer incidence.
    Ventura L; Mantellini P; Grazzini G; Castiglione G; Buzzoni C; Rubeca T; Sacchettini C; Paci E; Zappa M
    Dig Liver Dis; 2014 Jan; 46(1):82-6. PubMed ID: 24011791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sensitivity of latex agglutination faecal occult blood test in the Florence District population-based colorectal cancer screening programme.
    Castiglione G; Visioli CB; Ciatto S; Grazzini G; Bonanomi AG; Rubeca T; Mantellini P; Zappa M
    Br J Cancer; 2007 Jun; 96(11):1750-4. PubMed ID: 17453007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patterns of uptake in a biennial faecal occult blood test screening programme for colorectal cancer.
    Steele RJ; McClements PL; Libby G; Carey FA; Fraser CG
    Colorectal Dis; 2014 Jan; 16(1):28-32. PubMed ID: 24034143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interval faecal occult blood testing in a colonoscopy based screening programme detects additional pathology.
    Bampton PA; Sandford JJ; Cole SR; Smith A; Morcom J; Cadd B; Young GP
    Gut; 2005 Jun; 54(6):803-6. PubMed ID: 15888788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Colorectal adenocarcinomas diagnosed following a negative faecal immunochemical test show high-risk pathological features in a colon screening programme.
    Steel MJ; Bukhari H; Gentile L; Telford J; Schaeffer DF
    Histopathology; 2021 Apr; 78(5):710-716. PubMed ID: 33037645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A sensitive guaiac faecal occult blood test is less useful than an immunochemical test for colorectal cancer screening in a Chinese population.
    Wong BC; Wong WM; Cheung KL; Tong TS; Rozen P; Young GP; Chu KW; Ho J; Law WL; Tung HM; Lai KC; Hu WH; Chan CK; Lam SK
    Aliment Pharmacol Ther; 2003 Nov; 18(9):941-6. PubMed ID: 14616158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of tumour and host prognostic factors in screen-detected vs nonscreen-detected colorectal cancer: a contemporaneous study.
    Mansouri D; McMillan DC; McIlveen E; Crighton EM; Morrison DS; Horgan PG
    Colorectal Dis; 2016 Oct; 18(10):967-975. PubMed ID: 26859503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunochemical testing of individuals positive for guaiac faecal occult blood test in a screening programme for colorectal cancer: an observational study.
    Fraser CG; Matthew CM; Mowat NA; Wilson JA; Carey FA; Steele RJ
    Lancet Oncol; 2006 Feb; 7(2):127-31. PubMed ID: 16455476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Colorectal cancer incidence, mortality, tumour characteristics, and treatment before and after introduction of the faecal immunochemical testing-based screening programme in the Netherlands: a population-based study.
    Breekveldt ECH; Lansdorp-Vogelaar I; Toes-Zoutendijk E; Spaander MCW; van Vuuren AJ; van Kemenade FJ; Ramakers CRB; Dekker E; Nagtegaal ID; Krul MF; Kok NFM; Kuhlmann KFD; Vink GR; van Leerdam ME; Elferink MAG;
    Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):60-68. PubMed ID: 34822762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interval cancers in a community-based programme of colorectal cancer screening with faecal occult blood test.
    Tazi MA; Faivre J; Lejeune C; Bolard P; Phelip JM; Benhamiche AM
    Eur J Cancer Prev; 1999 Apr; 8(2):131-5. PubMed ID: 10335459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interval cancers in a FOBT-based colorectal cancer population screening programme: implications for stage, gender and tumour site.
    Steele RJ; McClements P; Watling C; Libby G; Weller D; Brewster DH; Black R; Carey FA; Fraser CG
    Gut; 2012 Apr; 61(4):576-81. PubMed ID: 21930729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.